Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial

•A randomised control trial of the efficacy of a nasal spray against SARS-CoV-2.•The spray combines natural viricidal agents with mechanisms to prevent viral entry.•The test agent significantly reduced the infection rate from 34.5% to 13.1%.•Fewer patients were symptomatic in the test group [17.6% v...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Journal of clinical virology 2022-10, Vol.155, p.105248-105248, Article 105248
Hauptverfasser:	Balmforth, Damian, Swales, James A, Silpa, Laurence, Dunton, Alan, Davies, Kay E., Davies, Stephen G., Kamath, Archana, Gupta, Jayanti, Gupta, Sandeep, Masood, M.Abid, McKnight, Áine, Rees, Doug, Russell, Angela J., Jaggi, Manu, Uppal, Rakesh
Format:	Artikel
Sprache:	eng
Schlagworte:	Clinical trial COVID-19 COVID-19 - prevention & control Humans Nasal Sprays Pandemics - prevention & control Prophylaxis Prospective Studies SARS-CoV-2
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	•A randomised control trial of the efficacy of a nasal spray against SARS-CoV-2.•The spray combines natural viricidal agents with mechanisms to prevent viral entry.•The test agent significantly reduced the infection rate from 34.5% to 13.1%.•Fewer patients were symptomatic in the test group [17.6% vs 34.6%; p
ISSN:	1386-6532 1873-5967 1873-5967
DOI:	10.1016/j.jcv.2022.105248